{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:15:25Z","timestamp":1792181725608,"version":"4.4.0"},"reference-count":31,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases","award":["HHSN272200800056C"],"award-info":[{"award-number":["HHSN272200800056C"]}]},{"name":"National Institute of Allergy and Infectious Diseases","award":["HHSN272201000006I|HHSN27200007"],"award-info":[{"award-number":["HHSN272201000006I|HHSN27200007"]}]},{"name":"National Institute of Allergy and Infectious Diseases","award":["HHSN272201200003I|HHSN27200008"],"award-info":[{"award-number":["HHSN272201200003I|HHSN27200008"]}]},{"name":"Vaccine Research Center","award":["HHSN272200800056C"],"award-info":[{"award-number":["HHSN272200800056C"]}]},{"name":"Vaccine Research Center","award":["HHSN272201000006I|HHSN27200007"],"award-info":[{"award-number":["HHSN272201000006I|HHSN27200007"]}]},{"name":"Vaccine Research Center","award":["HHSN272201200003I|HHSN27200008"],"award-info":[{"award-number":["HHSN272201200003I|HHSN27200008"]}]},{"name":"National Institutes of Health","award":["HHSN272200800056C"],"award-info":[{"award-number":["HHSN272200800056C"]}]},{"name":"National Institutes of Health","award":["HHSN272201000006I|HHSN27200007"],"award-info":[{"award-number":["HHSN272201000006I|HHSN27200007"]}]},{"name":"National Institutes of Health","award":["HHSN272201200003I|HHSN27200008"],"award-info":[{"award-number":["HHSN272201200003I|HHSN27200008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The Marburg virus (MARV) and Sudan virus (SUDV) belong to the filovirus family. The sporadic human outbreaks occur mostly in Africa and are characterized by an aggressive disease course with high mortality. The first case of Marburg virus disease in Guinea in 2021, together with the increased frequency of outbreaks of Ebola virus (EBOV), which is also a filovirus, accelerated the interest in potential prophylactic vaccine solutions against multiple filoviruses. We previously tested a two-dose heterologous vaccine regimen (Ad26.Filo, MVA-BN-Filo) in non-human primates (NHP) and showed a fully protective immune response against both SUDV and MARV in addition to the already-reported protective effect against EBOV. The vaccine-induced glycoprotein (GP)-binding antibody levels appear to be good predictors of the NHP challenge outcome as indicated by the correlation between antibody levels and survival outcome as well as the high discriminatory capacity of the logistic model. Moreover, the elicited GP-specific binding antibody response against EBOV, SUDV, and MARV remains stable for more than 1 year. Overall, the NHP data indicate that the Ad26.Filo, MVA-BN-Filo regimen may be a good candidate for a prophylactic vaccination strategy in regions at high risk of filovirus outbreaks.<\/jats:p>","DOI":"10.3390\/vaccines10081263","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T09:47:06Z","timestamp":1660124826000},"page":"1263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels"],"prefix":"10.3390","volume":"10","author":[{"given":"Machteld M.","family":"Tiemessen","sequence":"first","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Solforosi","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Dekking","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Czapska-Casey","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Volkmann","sequence":"additional","affiliation":[{"name":"Bavarian Nordic GmbH, Fraunhoferstrasse 13, D-82152 Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Pau","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Callendret","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-2266","authenticated-orcid":false,"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Luhn","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Roozendaal","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V., Archimedesweg 6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"ref_1","unstructured":"WHO (2022, May 05). West Africa\u2019s First-Ever Case of Marburg Virus Disease Confirmed in Guinea. Available online: https:\/\/www.afro.who.int\/news\/west-africas-first-ever-case-marburg-virus-disease-confirmed-guinea."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1411099","article-title":"Ebola virus disease in the Democratic Republic of Congo","volume":"371","author":"Maganga","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-021-03901-9","article-title":"Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks","volume":"597","author":"Keita","year":"2021","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1017\/S0950268816000054","article-title":"Persistence of Ebola virus in various body fluids during convalescence: Evidence and implications for disease transmission and control","volume":"144","author":"Chughtai","year":"2016","journal-title":"Epidemiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3201\/eid2502.181011","article-title":"Ebola virus infection associated with transmission from survivors","volume":"25","author":"Marsto","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_7","first-page":"457","article-title":"A hitherto unknown infectious disease contracted from monkeys. \u201cMarburg-virus\u201d disease","volume":"13","author":"Martini","year":"1968","journal-title":"Ger. Med. Mon."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3201\/eid1809.111536","article-title":"Reemerging Sudan Ebola virus disease in Uganda, 2011","volume":"18","author":"Shoemaker","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire Ebola virus disease in Guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nature19790","article-title":"The evolution of Ebola virus: Insights from the 2013\u20132016 epidemic","volume":"538","author":"Holmes","year":"2016","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Longini","year":"2015","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Callendret, B., Vellinga, J., Wunderlich, K., Rodriguez, A., Steigerwald, R., Dirmeier, U., Cheminay, C., Volkmann, A., Brasel, T., and Carrion, R. (2018). A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196546"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41541-020-00261-9","article-title":"Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate","volume":"5","author":"Roozendaal","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): A randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: A combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bockstal, V., Leyssen, M., Heerwegh, D., Spiessens, B., Robinson, C., Stoop, J.N., Roozendaal, R., Van Effelterre, T., Gaddah, A., and Van Roey, G.A. (2022). Nonhuman primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola virus disease. NPJ Vaccines, submitted.","DOI":"10.1038\/s41541-022-00564-z"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zahn, R., Gillisen, G., Roos, A., Koning, M., van der Helm, E., Spek, D., Weijtens, M., Grazia Pau, M., Radosevic, K., and Weverling, G.J. (2012). Ad35 and Ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044115"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.00069-06","article-title":"Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola","volume":"80","author":"Towner","year":"2006","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1093\/infdis\/jiv216","article-title":"Genetic changes at the glycoprotein editing site associated with serial passage of Sudan virus","volume":"212","author":"Alfson","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rudge, T.L., Sankovich, K.A., Niemuth, N.A., Anderson, M.S., Badorrek, C.S., Skomrock, N.D., Cirimotich, C.M., and Sabourin, C.L. (2019). Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215457"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10386","DOI":"10.1128\/JVI.00594-10","article-title":"Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates","volume":"84","author":"Geisbert","year":"2010","journal-title":"J. Virol."},{"key":"ref_23","unstructured":"R Foundation for Statistical Computing (2022, April 22). R: A Language and Environment for Statistical Computing. Available online: https:\/\/www.r-project.org\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection against Marburg virus using a recombinant VSV-vaccine depends on T and B cell activation","volume":"9","author":"Marzi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"774026","DOI":"10.3389\/fimmu.2021.774026","article-title":"Single dose of a VSV-based vaccine rapidly protects macaques from Marburg virus disease","volume":"12","author":"Marzi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hunegnaw, R., Honko, A., Wang, L., Carr, D., Murray, T., Shi, W., Dulan, C.N.M., Foulds, K.E., Agans, K.N., and Cross, R.W. (2021). Rapid and durable protection against Marburg virus with a single-shot ChAd3-MARV GP vaccine. bioRxiv, preprint.","DOI":"10.1101\/2021.12.22.472410"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/JVI.80.6.2738-2746.2006","article-title":"Development of a cAdVax-based bivalent Ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus","volume":"80","author":"Wang","year":"2006","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/CVI.00431-07","article-title":"Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections","volume":"15","author":"Swenson","year":"2008","journal-title":"Clin. Vaccine Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:04:53Z","timestamp":1760141093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["vaccines10081263"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10081263","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]}}}